12 citations
,
September 2012 in “Pediatric Dermatology” This case report describes a 5-year-old boy with extensive epidermal nevus who experienced marked improvement using a topical calcipotriol/betamethasone dipropionate combination ointment.
This article reviews interventions for preventing chemotherapy-induced alopecia and highlights scalp cooling as the only currently effective method, while noting its limitations and other potential options without providing new results.
May 1981 in “Inpharma (Balgowlah)” Medroxyprogesterone acetate improved sleep apnea symptoms in some obese patients.
8 citations
,
January 2016 in “Annals of Dermatology” This study found that the ALAVAX complex, containing 5-ALA and GHK peptide, may increase hair count in male pattern hair loss patients over 6 months without adverse events.
This study introduced ElixirSeeker2, a computational framework for designing anti-aging peptides, and found that some newly identified peptides significantly delayed cellular senescence and enhanced cellular and locomotor functions in aged Caenorhabditis elegans.
20 citations
,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” This review summarizes recent research and patents on 17β-HSD3, 17β-HSD5, and 3α-HSD3 inhibitors, suggesting their potential in treating androgen-dependent diseases, but reports no new clinical results.
This study tested a novel cryo-carboxy dispensing device for treating androgenetic alopecia in six volunteers and found an unexpectedly rapid and positive response, with significant hair regrowth observed by day 90, prompting early conclusion of the trial.
July 2025 in “Journal of Investigative Dermatology” TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
November 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” This study found that prostaglandin E2 pretreatment may reduce radiotherapy-induced alopecia by enhancing hair follicle self-repair through transient G1 arrest, suggesting a potential preventive treatment.
March 2026 in “Dermatology Online Journal” Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
14 citations
,
June 2013 in “Joint Bone Spine” This review discusses current anti-inflammatory treatment options for calcium pyrophosphate crystal deposition disease (CPPD) and highlights the lack of crystal-targeted therapies, emphasizing the need for more research to guide treatment.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.
January 2022 in “Drugs of Today”
1 citations
,
November 2018 in “Therapeutic Delivery” This industry update reports on various advancements in therapeutic delivery during July 2018, highlighting active mergers, collaborations, and potential developments across fields like gene therapy, immuno-oncology, and rare diseases treatment; however, no new clinical results are presented.
1 citations
,
February 2014 in “Analytical Letters” This study developed a fast and sensitive ultra-high performance liquid chromatography method to quantify ketoconazole in antidandruff emulsions, showing comparable results to labeled concentrations.
2 citations
,
November 2015 in “Endocrinology, Diabetes & Metabolism Case Reports” This case report describes a 57-year-old man's late diagnosis of X-linked adrenoleukodystrophy, highlighting the need to consider this condition in patients with non-autoimmune primary adrenal insufficiency and neurological issues.
8 citations
,
May 2019 in “Journal of dermatological treatment” This study found that vismodegib was effective in treating basal cell carcinoma, achieving complete remission in some patients; however, significant side effects often required careful management to prevent therapy suspension, which can lead to resistance.
17 citations
,
April 2016 in “Journal of Investigative Dermatology” This study found that the synthetic thyroid hormone receptor modulator KB2115 significantly prolonged the growth phase of human hair follicles in culture without altering mitochondrial activity, suggesting potential as a safer hair loss treatment compared to traditional thyroid hormones.
November 2003 in “PubMed” November 2024 in “SKIN The Journal of Cutaneous Medicine” This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.
23 citations
,
March 2019 in “Environmental Chemistry Letters” This review examines the role of cyclodextrins in improving the solubility, stability, and bioavailability of steroid drugs but does not report new experimental findings.
June 2025 in “Clinical Cancer Research” In this case report, researchers observed that scalp cooling during chemotherapy with doxorubicin and cyclophosphamide allowed a pregnant breast cancer patient to preserve nearly all her hair, suggesting such treatment may be a safe and effective option for managing chemotherapy-related hair loss during pregnancy.
March 2018 in “International journal of basic and clinical pharmacology” This study found that while the carboplatin-paclitaxel regimen for advanced lung cancer is more affordable than newer treatments and maintains a good performance status, it significantly increases risks of alopecia and peripheral neuropathy.
This report describes a case where a young woman developed Kerion Celsi, a fungal skin infection, potentially linked to the use of a tretinoin, minoxidil, and betamethasone valerate lotion.
6 citations
,
April 2014 in “European journal of medicinal chemistry” This study found that several newly synthesized dihydrobenzopyran compounds inhibited insulin secretion and had vasorelaxant activity, with some more potent than reference KATP channel activators, though compound 21 functioned as a Ca2+ entry blocker.
April 2025 in “European Journal of Pharmaceutics and Biopharmaceutics” This study developed and tested Bicalutamide-loaded lipid vesicles in dissolving microarray patches for topical application, finding that they effectively deliver Bicalutamide through murine skin while maintaining a favorable safety profile, suggesting potential to improve treatments for androgenetic alopecia.
18 citations
,
January 2021 in “Theranostics” This study found that actively targeted AN2728-loaded nanocarriers reduced inflammation and improved skin condition in a mouse model of psoriasiform inflammation compared to free drug and non-targeted nanoparticles.
2 citations
,
January 2025 in “Сибирский научный медицинский журнал” In this study using a mouse model, the authors reported that the synthetic antioxidant TS-13 effectively inhibited tumor growth comparably to doxorubicin and reduced chemotherapy side effects, such as weight loss, splenotoxicity, and alopecia, more effectively when combined with the cytostatic treatment.
January 2021 in “Global Dermatology” This study involved selecting patients with specific types of alopecia for treatment but does not report clinical outcomes.
December 2022 in “International Journal of Molecular Sciences” This study used machine learning to identify FDA-approved drugs afatinib, neratinib, and zanubrutinib as potential KRASG12C inhibitors for resistant non-small-cell lung cancer, highlighting the potential of AI in drug repurposing.